scispace - formally typeset
Y

Yanjing Bai

Researcher at University of Toyama

Publications -  6
Citations -  164

Yanjing Bai is an academic researcher from University of Toyama. The author has contributed to research in topics: Eleutherococcus senticosus & Eleutherococcus. The author has an hindex of 5, co-authored 6 publications receiving 135 citations.

Papers
More filters
Journal ArticleDOI

Active components from Siberian ginseng (Eleutherococcus senticosus) for protection of amyloid β(25-35)-induced neuritic atrophy in cultured rat cortical neurons.

TL;DR: In this article, a comprehensive evaluation of constituents from Siberian ginseng which can protect against neuritic atrophy induced by amyloid β (Aβ)(25-35) in cultured rat cortical neurons was conducted.
Journal ArticleDOI

Inhibitory Effects of Eleutherococcus senticosus Extracts on Amyloid β(25-35)–Induced Neuritic Atrophy and Synaptic Loss

TL;DR: Extracts of E. senticosus protect against neuritic atrophy and cell death under Abeta treatment, and one of active constituents may be eleutheroside B.
Journal ArticleDOI

Aristololactams and aporphines from the stems of Fissistigma oldhamii (Annonaceae).

TL;DR: The results demonstrated that the CHCl(3)-soluble part and alkaloid 2 exhibited significant anti-inflammatory activity in vitro in both assays.
Journal ArticleDOI

Genetic and chemical diversity of Eleutherococcus senticosus and molecular identification of Siberian ginseng by PCR-RFLP analysis based on chloroplast trnK intron sequence

TL;DR: Quantitative evaluation of three main bioactive constituents indicated chemical diversity in E. senticosus collected from northeast China and the results suggested good producing areas of SG, while chemical data clearly revealed that E. sessliflorus was unsuitable to be used as SG.
Journal ArticleDOI

Search of anti-allodynic compounds from Plantaginis Semen, a crude drug ingredient of Kampo formula "Goshajinkigan".

TL;DR: This study establishes that oral administration of 1 has potent anti-allodynic effect in addition to the activity of intraperitoneally administered 1 reported previously, which will support the development of novel therapies for the management of CIPN in cancer patients.